当前,双抗ADC凭借双重优势,成为药企差异化竞争的核心赛场。而中国双抗ADC药物领域,百利天恒、正大天晴、康宁杰瑞等正在不断实现跨越。其中,百利天恒的EGFR×HER3双抗ADC药物iza-bren(BL-B01D1)是重磅成果之一。2025年11月18日,百利天恒发布消息:iza-bren(BL-B01D1)在复发性或转移性食管鳞癌的III期临床试验(BL-B01D1-305)中,经独立数据监查...
Source Link当前,双抗ADC凭借双重优势,成为药企差异化竞争的核心赛场。而中国双抗ADC药物领域,百利天恒、正大天晴、康宁杰瑞等正在不断实现跨越。其中,百利天恒的EGFR×HER3双抗ADC药物iza-bren(BL-B01D1)是重磅成果之一。2025年11月18日,百利天恒发布消息:iza-bren(BL-B01D1)在复发性或转移性食管鳞癌的III期临床试验(BL-B01D1-305)中,经独立数据监查...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.